| [1] |
LI Shanshan, WEI Dandan, KANG Hanyu, LIU Xiaopeng, YAN Shuxun, JIANG Shiqing.
Research progress on the clinical application and mechanism of commonly used traditional Chinese medicine in the treatment of breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(7): 977-983.
|
| [2] |
WANG Feng, LIANG Luhua, ZHAI Fei, LUO Xiaoling, XIANG Rongwu.
Construction of a comprehensive prediction and visualization system for drug resistance in pulmonary tuberculosis patients based on an improved machine learning model
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(5): 673-682.
|
| [3] |
ZHANG Huihui, JIN Le, LIU Su, CHEN Hongxiao, CHEN Zhaolin, TANG Liqin.
Network pharmacological analysis of berberine inhibiting breast cancer cell proliferation and in vitro cell validation#br#
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(3): 332-338.
|
| [4] |
LIANG Hao, WANG Shun, CUI Cheng, SONG Ling, SUN Ailin, LI Man, QIAO Jie, SONG Chunli, LI Haiyan, ZHAO Yangguang, LI Haiyan, ZHANG Chenguang, LIU Dongyang.
Advances and future research prospects in regulatory policies for clinical trials of artificial intelligence medical devices
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(3): 427-431.
|
| [5] |
TAN Yanchen, WANG Wenwen, XIA Jielai, LI Chen.
Research on the application of machine learning algorithms in anticancer drug response prediction
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2025, 30(2): 200-208.
|
| [6] |
SHI Juan, JIANG Lin, MA Xiaopeng, WANG Jing, WANG Jiaoyuan, LUO Bin, WANG Tingting.
Latent profile analysis and influencing factors of self concealment in breast cancer patients
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(9): 1027-1034.
|
| [7] |
LI Ning, ZHANG Hui, ZHOU Junhui.
Effect of sub-anesthetic dose of esketamine on chronic post-surgery pain in patients undergoing radical mastectomy of breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(6): 671-679.
|
| [8] |
DU Caiying, QUAN Xianghua, SUN Caihong, YUAN Haidan.
Research progress of dalpiciclib in treatment of breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(6): 715-720.
|
| [9] |
WU Guilan, LIU Jia, SUN Hong.
Construction of a column-line graph for predicting the probability of survival in early-stage elderly HER2-positive breast cancer based on the SEER database
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2024, 29(3): 283-295.
|
| [10] |
HE Lihua, ZHU Xiuzhi, JIANG Yizhou.
Research progress on immunotherapy for triple-negative breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 842-853.
|
| [11] |
ZHANG Huyunlong, ZHU Xiuzhi, JIN Xi, SHAO Zhimin.
Mechanisms of endocrine-resistance and therapeutic breakthroughs in hormone receptor-positive, HER2-negative breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 854-865.
|
| [12] |
FU Xiaoyu, KONG Deguang, LI Juanjuan.
Treatment progress of triple positive breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 866-875.
|
| [13] |
LUO Shiping, ZHANG Jie, YU Yushuai, SONG Chuangui.
Advances in targeted therapy for HER2-positive breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 876-886.
|
| [14] |
XIANG Yimei, ZHANG Ningning, HUANG Yuxin, ZENG Xiaohua.
Research progress of biomarkers related to the efficacy of HER2 positive breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 887-897.
|
| [15] |
CHEN Keyu, HUANG Yuan, WANG Xiaojia, ZHENG Yabing.
Clinical application and research progress of antibody drugs conjugation in breast cancer
[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(8): 898-909.
|